LOWELL, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will present at the 41st Annual J.P. Morgan Healthcare Conference.
The Company is scheduled to present on Thursday, January 12, 2023 at 9:45am Pacific Time (12:45pm Eastern Time). A live webcast of the presentation will be available on the Rapid Micro Biosystems investor relations website at and can be accessed here. The webcast will be archived and available for replay for at least 30 days after the event.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company's flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control ("MQC") testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of in-line/at-the-line MQC automation to deliver faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making, that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Lexington, Massachusetts, Switzerland, Germany, and the Netherlands.
For more information, please visit or follow the Company on Twitter at @rapidmicrobio or on LinkedIn.
CONTACT: Investor Contact: Michael Beaulieu, CFA Vice President, Investor Relations and Corporate Communications mbeaulieu@rapidmicrobio.com Media Contact: media@rapidmicrobio.com
洛厄爾，馬薩諸塞州，2023年1月5日(環球網)--快速微生物系統公司(納斯達克代碼：RFID)(以下簡稱公司)，一家提供關鍵任務自動化解決方案的創新生命科學技術公司，今天宣佈，該公司將出席第41屆世界衛生保健大會。ST一年一度的摩根大通醫療會議。
該公司定於2023年1月12日(星期四)太平洋時間上午9：45(美國東部時間下午12：45)提交報告。演講的現場網路直播將在Rapid Micro BiosSystems投資者關係網站上提供，並可在此處訪問。網路直播將被存檔，並在活動結束後至少30天內可供重播。
關於快速微生物系統
快速微生物生物系統公司是一家創新的生命科學技術公司，提供關鍵任務自動化解決方案，以促進生物製劑、疫苗、細胞和基因療法以及無菌注射劑等保健產品的高效製造和快速、安全釋放。該公司的旗艦產品Growth Direct系統自動化和現代化了過時的手動微生物質量控制(“MQC”)測試工作流程，這些工作流程用於全球規模最大、最複雜的製藥生產業務。Growth Direct系統將質量控制實驗室帶到了製造車間，釋放了在線/在線MQC自動化的力量，以提供更快的結果、更高的準確性、更高的運營效率、更好地遵守數據完整性法規和更快的決策，客戶依靠這些來確保重要保健產品的安全和一致供應。該公司總部設在馬薩諸塞州洛厄爾，在美國設有工廠，在馬薩諸塞州列剋星敦、瑞士、德國和荷蘭設有全球辦事處。
欲瞭解更多資訊，請訪問網站，或在推特上或在LinkedIn上關注該公司。
媒體聯繫人：Media@RapidmicroBio.com媒體聯繫：媒體@RapidmicroBio.com媒體聯繫：Media@RapidmicroBio.com媒體聯繫：媒體@RapidmicroBio.com媒體聯繫：Media@RapidmicroBio.com媒體聯繫：媒體@RapidmicroBio.com媒體聯繫：Media@RapidmicroBio.com
